Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

Aishwarya Prasad; Anshu Arora; Arun Arora; Jeena Vaid; Arif Khan

doi:10.1002/bcp.70515

March 27, 2026British Journal of Clinical PharmacologyOpen Access

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

View Full Paper

Ask AI

Bookmark

Share

Key Points

To compare the safety and efficacy of GLP-1 receptor agonists and non-GLP-1 agents for weight management in type 2 diabetes.
Used FDA medical and statistical reports for analysis.
Compared GLP-1 receptor agonists, GLP-1/GIP dual agonists, and non-GLP-1 agents.
Analyzed safety in 34,280 subjects and efficacy in 36,312 subjects.
Tirzepatide and liraglutide showed the greatest weight reductions.
Efficacy outcomes were generally favorable.
Safety signals were limited due to small sample sizes.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Analysis reveals greater weight loss with GLP-1 agonists in type 2 diabetes, suggesting a need for real-world evidence on safety.

Abstract

Using FDA regulatory data, we compared GLP-1 RAs, GLP-1/GIP dual agonists and non-GLP-1 weight loss agents, finding the greatest weight reductions with tirzepatide and liraglutide. While efficacy outcomes were favourable, safety signals were limited by small sample sizes. Expanded real-world evidence is needed to better characterize long-term safety.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Prasad et al. (2026) studied this question.

synapsesocial.com/papers/69c9c5c5f8fdd13afe0bdb6c https://doi.org/10.1002/bcp.70515

View Full Paper

Ask AI

Bookmark

Share

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading